Subcutaneously administered ofatumumab in rheumatoid arthritis: A phase i/ii study of safety, tolerability, pharmacokinetics, and pharmacodynamics

Journal of Rheumatology

Volumn 40, Issue 7, 2013, Pages 1089-1096

  Kurrasch, Regina ^a   Brown, Judith C ^b   Chu, Myron ^a   Craigen, Jenny ^b   Overend, Philip ^b   Patel, Bela ^a   Wolfe, Steven ^b   Chang, David J ^a  

^a GLAXOSMITHKLINE   (United States)

^b NONE

Author keywords

B Lymphocytes; Biological Therapy; Clinical Trials; Pharmacokinetics; Rheumatoid Arthritis

Indexed keywords

ANTIHISTAMINIC AGENT; IMMUNOGLOBULIN; METHOTREXATE; MONOCLONAL ANTIBODY; OFATUMUMAB; PARACETAMOL; PLACEBO; RITUXIMAB;

ADULT; AREA UNDER THE CURVE; ARTICLE; B LYMPHOCYTE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE EXACERBATION; DIZZINESS; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FEVER; HEADACHE; HUMAN; HUMORAL IMMUNE DEFICIENCY; HYPERTENSION; LOW DRUG DOSE; MALE; MULTICENTER STUDY; NAUSEA; PHARMACODYNAMICS; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PREMEDICATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHEUMATOID ARTHRITIS; SINGLE DRUG DOSE; UPPER RESPIRATORY TRACT INFECTION;

B LYMPHOCYTES; BIOLOGICAL THERAPY; CLINICAL TRIALS; PHARMACOKINETICS; RHEUMATOID ARTHRITIS;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; HYPODERMOCLYSIS; MALE; METHOTREXATE; MIDDLE AGED; SINGLE-BLIND METHOD; TREATMENT OUTCOME;

EID: 84879940364     PISSN: 0315162X     EISSN: 14992752     Source Type: Journal    
DOI: 10.3899/jrheum.121118     Document Type: Article

References (19)

1. Teeling JL, Mackus WJ, Wiegman LJ, van den Brakel JH, Beers SA, French RR, et al. The biological activity of human CD20 monoclonal antibodies is linked to unique epitopes on CD20. J Immunol 2006;177:362-71.
2. Genovese MC, Kaine JL, Lowenstein MB, Baldassare A, Schechtman J, Fudman E, et al. Ocrelizumab, a humanized anti-CD20 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: A phase I/II randomized, blinded, placebo-controlled, dose-ranging study. Arthritis Rheum 2008;58:2652-61.
3. Goldenberg DM, Rossi EA, Stein R, Cardillo TM, Czuczman MS, Hernandez-Ilizaliturri FJ, et al. Properties and structure-function relationships of veltuzumab (hA20), a humanized anti-CD20 monoclonal antibody. Blood 2009;113:1062-70.
4. Teeling JL, French RR, Cragg MS, van den Brakel J, Pluyter M, Huang H, et al. Characterization of new human CD20 monoclonal antibodies with potent cytolytic activity against non-Hodgkin lymphomas. Blood 2004;104:1793-800.
5. Cragg MS, Walshe CA, Ivanov AO, Glennie MJ. The biology of CD20 and its potential as a target for mAb therapy. Curr Dir Autoimmun 2005;8:140-74.
6. Glennie MJ, French RR, Cragg MS, Taylor RP. Mechanisms of killing by anti-CD20 monoclonal antibodies. Mol Immunol 2007;44:3823-37.
7. Bleeker WK, Munk ME, Mackus WJ, van den Brakel JH, Pluyter M, Glennie MJ, et al. Estimation of dose requirements for sustained in vivo activity of a therapeutic human anti-CD20 antibody. Br J Haematol 2008;140:303-12.
8. Ostergaard M, Baslund B, Rigby W, Rojkovich B, Jorgensen C, Dawes PT, et al. Ofatumumab, a human anti-CD20 monoclonal antibody, for treatment of rheumatoid arthritis with an inadequate response to one or more disease-modifying antirheumatic drugs: Results of a randomized, double-blind, placebo-controlled, phase I/II study. Arthritis Rheum 2010;62:2227-38.
9. Emery P, Fleischmann R, Filipowicz-Sosnowska A, Schechtman J, Szczepanski L, Kavanaugh A, et al. The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: Results of a phase IIb randomized, double-blind, placebo-controlled, dose-ranging trial. Arthritis Rheum 2006;54:1390-400.
10. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-24.
11. Yazici Y, McMorris BJ, Darkow T, Rosenblatt LC. Patient and physician perception of the infusion process of the biologic agents abatacept, infliximab, and rituximab for the treatment of rheumatoid arthritis. Clin Exp Rheumatol 2009;27:907-13.
12. Osterborg A, Foa R, Bezares RF, Dearden C, Dyer MJ, Geisler C, et al. Management guidelines for the use of alemtuzumab in chronic lymphocytic leukemia. Leukemia 2009;23:1980-8.
13. Ternant D, Paintaud G. Pharmacokinetics and concentration-effect relationships of therapeutic monoclonal antibodies and fusion proteins. Expert Opin Biol Ther 2005;5 Suppl 1:S37-47.
14. Moller B, Aeberli D, Eggli S, Fuhrer M, Vajtai I, Vögelin E, et al. Class-switched B cells display response to therapeutic B-cell depletion in rheumatoid arthritis. Arthritis Res Ther 2009;11:R62.
15. Leandro MJ, Cambridge G, Ehrenstein MR, Edwards JC. Reconstitution of peripheral blood B cells after depletion with rituximab in patients with rheumatoid arthritis. Arthritis Rheum 2006;54:613-20.
16. Roll P, Dörner T, Tony HP. Anti-CD20 therapy in patients with rheumatoid arthritis: Predictors of response and B cell subset regeneration after repeated treatment. Arthritis Rheum 2008;58:1566-75.
17. Cambridge G, Stohl W, Leandro MJ, Migone T, Hilbert DM, Edwards JC. Circulating levels of B lymphocyte stimulator in patients with rheumatoid arthritis following rituximab treatment. Arthritis Rheum 2005;54:723-32.
18. Fleischmann R, Cohen S, Pardo P, Dessouki E, Clowse M, Korth-Bradley J, et al. Subcutaneous (SC) administration of SBI-087 provides potent B cell depletion in subjects with controlled RA [abstract]. Ann Rheum Dis 2010;69 Suppl 3:69.
19. Damjanov N, Tlustochowicz M, Aelion J, Dimic M, Greenwald M, Diehl A, et al. Safety and efficacy of SBI-087 in subjects with active rheumatoid arthritis in a phase 2 randomized, double-blind, placebo-controlled study [abstract]. Ann Rheum Dis 2012;71 Suppl 3:60.